PubMed Health⌕ Search

Biomedical subjects

S B Gusberg

Publications and source records attributed to S B Gusberg.

At least 19 recordsLinked to original sources
PubMed1979

A blocking factor in amniotic fluid causing leukocyte migration enhancement.

Amniotic fluid was found to cause significant leukocyte migration enhancement during the second and third trimester of pregnancy and in the early postpartum period when compared to the migration area obtained with an ovarian tumor homogenate antigen (p less than 0.01), choriocarcinoma spent medium (p less than 0.01), and placental pool homogenate (p less than 0.01). Only borderline significance (p less than 0.1) was obtained when migration enhancement with AF was compared between pregnant and nonpregnant female control patients, indicating minimal unspecific activity of AF. Migration enhancement with autologous amniotic fluid was slightly larger than with homologous amniotic fluid, but the difference did not reach significance (p less than 0.4). None of the control antigens caused migration enhancement; placental pool homogenate in concentrations above 4 mg. per cent caused migration inhibition but did not in lower concentrations. The enhancing effect of AF could be abolished by dilution but not by addition of excessive antibody to estrogen of HCG. It is suggested that a blocking factor is present in AF preventing recognition of fetoplacental antigen by the maternal immune system. Thus in vitro leukocyte migration enhancement may correlate to in vivo graft enhancement.

Amniotic Fluid↗
PubMed1979

Familial malignant melanoma of the female genitalia: a case report and review.

An additional case of familial occurrence of malignant melanoma is presented, involving mother and son. This is the fourth case of familial occurrence of malignant melanoma in the female genitalia and the first occurring in the vagina reported in the literature. We present a review of the literature concerning the hereditary property of malignant melanoma, including a list of all 92 families and 240 patients reported. The importance of a family history of malignant melanoma for the early diagnosis of this disease in relatives at risk is stressed.

Adult↗
PubMed1978

Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy.

Nineteen patients with advanced ovarian adenocarcinoma were treated with cis-dichlorodiammineplatinum(II) (DDP), 50 mg/m2 as an iv bolus once every 3 weeks. Prior treatment had exhausted other chemotherapeutic options or damaged the bone marrow sufficiently to contra-indicate treatment with standard drugs. All patients had evaluable tumors and evidence of failure of prior therapy. DDP produced objective responses, relieved symptoms due to tumor, and improved the patients' quality of survival. There were no serious hematologic complications due to therapy except anemia.

Adenocarcinoma↗
PubMed1977

Estrogen metabolism in normal and neoplastic endometrium.

Studies on normal endometrium at different phases of the menstrual cycle have shown that progesterone and synthetic progestins reduce the levels of estradiol receptors in the tissue and increase the activity of estradiol-17beta-dehydrogenase, an enzyme that converts estradiol to estrone. These effects may account for the antiestrogenic characteristics of the progestins. Similar effects were obtained in some postmenopausal patients with endometrial adenocarcinoma treated for two to 10 days with oral medroxyprogesterone acetate. These results point to the potential usefulness of a short-term, in vivo biochemical test which, combined with histologic observations, may identify patients who are likely to respond to treatment with progestins.

Adenocarcinoma↗
PubMed1977

Radiosensitivity testing, virulence indices, and stromal reaction in carcinoma of the cervix uteri.

A relatively simple, clinically applicable, analytic-pathologic approach to the complex problem of carcinoma of the uterine cervix is given. Careful study of control and post-test radiation cervical biopsies and evaluation of the type and grade of the carcinoma, the lymphatic vessel involvement, the stromal host reaction, and the tumor response to test radiation offer additional parameters in the therapeutic approach, aiming at the improvement of prognosis. We also hope that this work offers a contribution to the complex problem of tumor biology and pathology.

Biopsy↗
PubMed1976

The individual at high risk for endometrial carcinoma.

Epidemiologic studies can help us recognize high-risk factors in endometrial carcinoma. The definition of high-risk factors, especially at the menopause,can lead to prophylactic measures that may aid in the control of this disease. This recognition of the high-risk patient in the perimenopausal years may be aided by aspiration curettage of ambulatory women, for such a strategy of surveillance is practical and efficient. Increasing acceptance of hormone sensitivity in neoplastic abnormality of the endometrium can also influence us in identifying the patient at risk.

Adult↗
PubMed1976

The evolution of modern treatment of corpus cancer.

The treatment of endometrial cancer has been surgical, traditionally, with preoperative radiation gaining favor in the past three decades. This surgical treatment has been confined to simple hysterectomy and bilateral salpingo-oophorectomy in most clinics because of the pattern of spread of corpus cancer and the alleged benignity of this disease. Even now, the role of radical surgery, the timing of radiation therapy and its mode, and the place of hormonal treatment for primary disease are still the subject of discussion and clinical investigation. The definition of virulence factors and an appropriate staging dependent upon these factors has helped to clarify some of these problems and will help the analysis of cure rates when we can understand the selection of the material. With such a prospect for quality control and establishment of a protocol of individualization of treatment, we have a right to expect that appropriate surgical and radiotherapeutic measures will gain their proper priority and adjuvant hormonal therapy and chemotherapy may be incorporated.

Female↗
PubMed1975

Screening for endometrial cancer.

Since Gusberg's description in 1947 of adenomatous hyperplasia (15), the role of precursors in the development of endometrial carcinoma has been well studied. There is now no doubt that in many patients histologic precursors can be demonstrated in the endometrial cavity prior to the development of invasive cancer. At this point in the continuum, interruption by hysterectomy or other therapy will insure the patient's health. We have discussed a wide variety of techniques designed to provide cytologic or histologic samples of the endometrium that are highly effective in the detection of early neoplasia. As a goal, universal endometrial sampling on a periodic basis is probably impractical and may be unecessary or undesirable. However, surely the patient at high risk for endometrial cancer requires close periodic screening. The high-risk category may be expanded to include others beyond the group of hypertensive, diabetic, obese, anovulatory, nulliparous women. It should include patients with irregular vaginal bleeding, those with a strong family history of genital and breast cancer, those patients receiving hormone therapy, and patients in the menopausal years who experience changes in the menstrual pattern. With intelligent and aggressive application of outpatient screening, uterine cancer can be diagnosed when patients are virtually completely curable, thus resulting in further reduction in mortality from this disease.

Adenocarcinoma↗
PubMed1975

President's remarks.

Explore the source record for details and available documents.

Academies and Institutes↗
PubMed1975

A strategy for the control of endometrial cancer.

Epidemiologic studies can provide us with etiological clues and help us recognize high risk factors. The definition of high risk factors, especially in the perimenopausal years can lead to prophylactic measures that may aid in the control of endometrial cancer. Recognition of the high risk patient in the perimenopausal years by aspiration curettage of ambulatory women may offer a significant strategy of surveillance. The advent of modern steroid metabolic technology promises to help us clarify the problems of hormone sensitivity of this tumor so that we may properly translate these data into therapeutic action. Virulence scales can help the choice of treatment for invasive carcinoma so that patients with tumors of low virulence do not suffer from an excess of complications nor those with tumors of high virulence an excess of failure to control. In this manner we can define the role of radiotherapy and surgery, elect combined treatment when indicated and select radical surgery as indicated. There is evidence to suggest that the developmental concept of this tumor may lead to its control in a manner similar to that occurring with cervix cancer.

Adenoma↗